

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 14 July 2022.

I am pleased to confirm the following.

Q1. Does your trust treat patients with Diffuse Large B Cell Lymphoma (DLBCL)? If not, then which trust do you refer DLBCL patients to?

We do treat DLBCL patients at MKUH

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL)?

24 patients have received Systemic anti-cancer therapy at MKUH in the last 6 months

Q3. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) = 18
- R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) = 2
- Other immuno-chemotherapy = 0
- Other chemotherapy = 16
- Stem cell transplant or bone marrow transplant (autologous or allogeneic) = 0 - we do not offer stem cell/ bone marrow transplant here
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - any line of treatment = 1
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - third-line treatment only = 1
- Tisagenlecleucel = 0
- Axicabtagene ciloleucel = 0
- Lisocabtagene maraleucel = 0

Q4. In the last 6 months, how many Diffuse Large B Cell Lymphoma (DLBCL) patients have you referred to other trusts for:

- Stem cell transplant or bone marrow transplant (autologous or allogeneic)

1 patient

- **CAR-T therapy (Tisagenlecleucel, Axicabtagene ciloleucel, Lisocabtagene maraleucel)**
- 3 patients

Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

We have REMoDL-A open- there are currently 4 patients enrolled in this

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.